Related Experiment Video

Updated: Mar 11, 2026

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

16.1K

New emerging therapies in the management of chronic lymphocytic leukemia

Xiao-Lin Li1, Ci-Xian Zhang2

  • 1Department of Cardiology, Xuzhou Central Hospital, The Affiliated Xuzhou Hospital of Medical College of Southeast University, Xuzhou, Jiangsu 221009, P.R. China.

Oncology Letters
|December 1, 2016
PubMed

Insights

New drugs targeting cell pathways offer hope for managing chronic lymphocytic leukemia (CLL), an incurable cancer. This review explores emerging strategies like antibody therapies and small molecule inhibitors for better CLL treatment.

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Chronic lymphocytic leukemia (CLL) remains incurable despite current management strategies.
  • Advances in understanding CLL cell pathways have spurred the development of novel therapeutic targets.
  • There is a critical need for innovative treatments to improve patient outcomes in CLL.

Purpose of the Study:

  • To review emerging and novel therapeutic strategies for the management of chronic lymphocytic leukemia (CLL).
  • To examine pre-clinical and clinical trial data on new agents targeting CLL.
  • To provide an overview of ongoing research into innovative CLL treatments.

Main Methods:

  • A comprehensive literature search was conducted in the PubMed electronic database.
  • The search focused on pre-clinical studies and controlled clinical trials investigating novel CLL strategies.
  • The review synthesized information on various therapeutic targets and agents.

Main Results:

  • Novel strategies include antibody-based therapies targeting CD20, CD37, CD23, and CD40.
  • Small molecule inhibitors targeting key signaling pathways such as SYK/LYN, BTK, and PI3K are under investigation.
  • Emerging agents include cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) inhibitors.

Conclusions:

  • Several novel therapeutic strategies show promise for the efficient management of CLL.
  • Targeted therapies offer a new frontier in the treatment of this challenging leukemia.
  • Continued research and clinical trials are essential to realize the full potential of these emerging treatments for CLL.
Keywords:
antibodieschronic lymphocytic leukemiaimmunotherapyleukemiatargeted therapy

More Related Videos

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.9K
Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

22.6K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K